Beam Therapeutics Inc.
risto-cel
sickle cell disease (SCD)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on risto-cel for sickle cell disease (SCD) is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“Beam expects to submit a BLA for risto-cel as early as year-end 2026.”